Quantcast

Latest Rodenticides Stories

2014-07-15 12:23:54

RnRMarketResearch.com adds "Rodenticides Market by Type (Anticoagulants, Non-Anticoagulants, and Others), by End User (Agricultural Field, Warehouses, Pest Control Companies, Urban Centers, and Others) & by Geography - Global Trends & Forecasts to 2019" to its store. DALLAS, July 15, 2014 /PRNewswire-iReach/ -- The rodenticides market size is projected to increase due to the demand for food grains and rising farmers concerns over food wastage due to rodents. Rodenticides are also used in...

2014-05-30 12:22:42

Rodent control market leader reaches agreement with U.S. EPA to discontinue production of second generation pellets by December 31 PARSIPPANY, N.J., May 30, 2014 /PRNewswire/ -- d-CON®, America's number one rodent control brand, announced an agreement today with the U.S. Environmental Protection Agency (EPA) regarding the production and distribution of second generation rodenticide pellets. Certain d-CON® rodenticide products have been subject to a lengthy review by the EPA and,...

2014-05-13 12:27:29

IPRO-designed "MAP" Tool Addresses How to Handle Numerous Patient Situations, In Order to Reduce Risk of Both Excessive Bleeding and Formation of Blood Clots LAKE SUCCESS, N.Y., May 13, 2014 /PRNewswire-USNewswire/ -- A new, free-of-charge tool designed by the Peri-Procedural Task Force of the IPRO-led New York State Anticoagulation Coalition will enable clinicians to more easily determine how, whether and when to stop the use of warfarin and other anticoagulants prior to surgery and...

2014-05-12 11:38:13

Intermountain Medical Center Study included 2,600 AFib patients A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City has found that atrial fibrillation patients who are on blood thinning medications are at higher risk of developing dementia if their doses are not in the optimal recommended range. The study of more than 2,600 AFib patients found they are significantly more likely to develop dementia when using medicines to prevent blood...

2014-04-29 08:34:35

Recently Released ACC/AHA Practice Guidelines Reinforce Unmet Need MENLO PARK, Calif., April 29, 2014 /PRNewswire/ -- Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin. Tecarfarin is positioned to be the only oral anticoagulant (OAC) therapy for patients with prosthetic heart valves (PHV) specifically identified in the label. In addition, the...

2014-03-26 23:27:31

Lead Investigator Discusses Findings With AJMC, Says Results Show Importance of Self-Testing Plainsboro, NJ (PRWEB) March 26, 2014 The American Journal of Managed Care (AJMC), on Monday published the results of the Self-Testing Analysis Based on Long-Term Experience (STABLE) study. It showed that self-testing significantly improves control of warfarin, as measured by time in therapeutic range (TTR). Results of the study, supported by Alere, were originally shared at the 2012 Scientific...

2014-03-13 00:21:16

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3d7f2f/aluminium) have announced the addition of the "Aluminium phosphide (CAS 20859-73-8) Market Research Report" [http://www.researchandmarkets.com/research/3d7f2f/aluminium ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Aluminium phosphide (CAS 20859-73-8) Market Research Report presents comprehensive data on aluminium...

2014-03-05 14:40:37

Although some research has suggested that the use of the anticoagulant warfarin for atrial fibrillation among patients with chronic kidney disease would increase the risk of death or stroke, a study that included more than 24,000 patients found a lower l-year risk of the combined outcomes of death, heart attack or stroke without a higher risk of bleeding, according to a study in the March 5 issue of JAMA. Juan Jesus Carrero, Ph.D., of the Karolinska Institutet, Stockholm, and colleagues...

2014-02-04 12:26:39

The Quest Diagnostics Health Trends(TM) study of 2.7 million test results is the largest to examine warfarin treatment in patients with atrial fibrillation (Afib) treated in primary care and other non-hospital care settings in the United States MADISON, N.J., Feb. 4, 2014 /PRNewswire/ -- Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy,...

2013-12-19 11:47:26

Patients with atrial fibrillation – an irregular and often abnormally fast heartbeat – have nearly double the risk of suffering a stroke in the first 30 days after starting to take the anti-clotting drug warfarin compared to non-users, according to a study of over 70,000 patients. The study, published online today (Thursday) in the European Heart Journal, found that the risk was particularly high in the first week after patients started to take the drug. In contrast, once the first 30...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related